GlassScriptPhysician profile
Sughosh Dhakal
NPI 1184823841
$2,084.16
in general payments reported to CMS, 2019-2025
18 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $768 · 2024: $846 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $562.00 | 2023-2025 | Erleada, Rybrevant |
| Sumitomo Pharma America, INC. | $419.46 | 2023-2025 | Orgovyx, Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $219.37 | 2023-2024 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $208.73 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $119.26 | 2025 | |
| Urogen Pharma, INC. | $96.21 | 2024 | |
| Merck Sharp & Dohme LLC | $80.58 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Teleflex LLC | $69.30 | 2023-2024 | Urolift |
| Abbvie INC. | $61.99 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $47.24 | 2024 | Adstiladrin |
| Novocure INC. | $34.11 | 2023 | Optune |
| Astrazeneca Pharmaceuticals LP | $33.97 | 2023-2025 | Tagrisso |
| Myriad Genetic Laboratories, INC. | $32.87 | 2023-2025 | Myrisk |
| Accord Healthcare, INC. | $21.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.19 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $19.77 | 2024 | |
| Novo Nordisk INC | $19.75 | 2025 | Rivfloza |
| Olympus America INC. | $18.03 | 2023 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sughosh Dhakal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.